tbuckley/cabot-search huggingface dataset:
Actividades y resultados del EARSS: actualización
Authors: U Buchholz, S L A M Bronzwaer, P Schrijnemakers, J Monen, J. L. Kool
Journal: Eurosurveillance (2001)

Los ultimos resultados del EARSS (1990–2000) sugieren que las tasas de S. aureus resistentes a la meticilina y de S. pneumoniae de sensibilidad reducida a la penicilina son mas altas en los paises del sur de Europa que en los del norte. Para las cepas de S. pneumoniae de sensibilidad reducida a la penicilina, el grupo de mayor riesgo es el de los ninos pequenos, seguido del de los ancianos. El riesgo de infeccion por S. aureus resistente a la meticilina aumenta con la edad, estando mas expuestos al riesgo de infeccion los enfermos hospitalizados en unidades de cuidados intensivos.
Dietary Restriction and AMPK Increase Lifespan via Mitochondrial Network and Peroxisome Remodeling
Authors: Heather J. Weir, Pallas Yao, Frank K. Huynh, Caroline C. Escoubas, Renata L. Goncalves, Kristopher Burkewitz, Raymond Laboy, Matthew D. Hirschey, William B. Mair
Journal: Cell Metabolism (2017)
Porous composite scaffold incorporating osteogenic phytomolecule icariin for promoting skeletal regeneration in challenging osteonecrotic bone in rabbits
Authors: Yuxiao Lai, Huijuan Cao, Xinluan Wang, Shukui Chen, Ming Zhang, Nan Wang, Zhihong Yao, Yi Dai, Xinhui Xie, Peng Zhang, Xinsheng Yao, Ling Qin
Journal: Biomaterials (2017)
Hepatitis B vaccine shortage: another symptom of chronic neglect?
Authors: Philippa C Matthews, Eleanor Barnes
Journal: BMJ (2017)

Current shortages of the hepatitis B virus vaccine have created media interest, including in The BMJ .1 Hepatitis B should make headlines; an estimated 250 million people are chronically infected, and funding, political advocacy, research, and clinical services have been neglected. International sustainable development goals aspire towards elimination of viral hepatitis as a public health threat by 2030.2 Vaccination is a crucial component of the multipronged effort needed to meet these targets.

Hepatitis B vaccine for routine infant vaccination …
JAK Inhibitors Taking on Psoriatic Arthritis
Authors: Robert A. Colbert, Michael M. Ward
Journal: New England Journal of Medicine (2017)

Psoriasis is a chronic inflammatory skin disease that affects 2 to 4% of the population.1 Inflammatory arthritis develops in approximately 30% of patients with psoriasis and can have a major effect on activities of daily living and quality of life.2 Peripheral joint involvement in patients with psoriatic arthritis can be oligoarticular or polyarticular and can cause joint destruction. Several medications are used to treat psoriatic arthritis, and the choice of agent and the timing of administration in the course of the disease depend on disease manifestations, their severity, and prognostic factors.2 Therapy typically involves the sequential use of nonsteroidal antiinflammatory . . .
TCT-9 Absorb Bioresorbable Vascular Scaffold vs. Everolimus-eluting Metallic Stent in Small Vessel Disease: a Propensity Matched Analysis of COMPARE II, RAI and MAASSTAD-ABSORB Prospective Studies
Authors: Giulia Masiero, Marco Mojoli, Alberto Barioli, Valeria Paradies, Bernardo Cortese, Gaetano di Palma, Attilio Varricchio, Alfonso Ielasi, Bruno Loi, Mostafa Rabea Abdelhaleem Badawy, Paola Tellaroli, Giuseppe Steffenino, Pieter Smits, Giuseppe Tarantini
Journal: Journal of the American College of Cardiology (2017)
Future cancer research priorities in the USA: a Lancet Oncology Commission
Authors: Elizabeth M Jaffee, Chi Van Dang, David B Agus, Brian M Alexander, Kenneth C Anderson, Alan Ashworth, Anna D Barker, Roshan Bastani, Sangeeta Bhatia, Jeffrey A Bluestone, Otis Brawley, Atul J Butte, Daniel G Coit, Nancy E Davidson, Mark Davis, Ronald A DePinho, Robert B Diasio, Giulio Draetta, A Lindsay Frazier, Andrew Futreal, Sam S Gambhir, Patricia A Ganz, Levi Garraway, Stanton Gerson, Sumit Gupta, James Heath, Ruth I Hoffman, Cliff Hudis, Chanita Hughes-Halbert, Ramy Ibrahim, Hossein Jadvar, Brian Kavanagh, Rick Kittles, Quynh-Thu Le, Scott M Lippman, David Mankoff, Elaine R Mardis, Deborah K Mayer, Kelly McMasters, Neal J Meropol, Beverly Mitchell, Peter Naredi, Dean Ornish, Timothy M Pawlik, Jeffrey Peppercorn, Martin G Pomper, Derek Raghavan, Christine Ritchie, Sally W Schwarz, Richard Sullivan, Richard Wahl, Jedd D Wolchok, Sandra L Wong, Alfred Yung
Journal: The Lancet Oncology (2017)
Temperature-Sensitive Gold Nanoparticle-Coated Pluronic-PLL Nanoparticles for Drug Delivery and Chemo-Photothermal Therapy
Authors: Ying Sun, Qi Wang, Jianhua Chen, Lei Liu, Li Ding, Ming Shen, Jin Li, Baoshan Han, Yourong Duan
Journal: Theranostics (2017)

Gold nanoparticle-coated Pluronic-b-poly(L-lysine) nanoparticles (Pluronic-PLL@Au NPs) were synthesized via an easy one-step method and employed as carriers for the delivery of paclitaxel (PTX) in chemo-photothermal therapy, in which Pluronic-PLL acts as the reductant for the formation of AuNPs without the need for an additional reducing agent.The deposition of AuNPs on the surface of Pluronic-PLL micelles and the thermal response of the system were followed via ultraviolet-visible spectroscopy and dynamic light scattering. Calcein-AM and MTT assays were used to study the cell viability of MDA-MB-231 cells treated with PTX-loaded Pluronic-PLL@Au NPs, and we then irradiated the cells with NIR light.An obvious temperature response was observed for the Pluronic-PLL@Au NPs. Blood compatibility and in vitro cytotoxicity assays confirmed that the Pluronic-PLL@Au NPs have excellent biocompatibility. Compared to Taxol, the PTX-loaded Pluronic-PLL@Au NPs exhibited higher cytotoxicity in MDA-MB-231 cells. All of these results and confocal laser scanning microscopy analysis results suggest that Pluronic-PLL@Au NPs greatly enhance the cellular uptake efficiency of the drug.As confirmed by in vitro and in vivo studies, the combination of chemotherapy and photothermal therapy can cause more damage than chemo- or photothermal therapy did alone, demonstrating the synergistic effect of chemo-photothermal treatment. Thus, the as-prepared Pluronic-PLL@Au NPs are promising for chemo-photothermal therapy.
Hombres que tienen relaciones sexuales con hombres y la prevención del VIH/SIDA en Suiza: 1987-2000
Authors: F Dubois-Arber, F Moreau-Gruet
Journal: Eurosurveillance (2002)

Aunque el ultimo estudio sobre los comportamientos preventivos de hombres que tienen relaciones sexuales con hombres (HRSH) en Suiza demuestra que, desde 1992, ha habido una reduccion en el numero de casos de VIH, tambien se observa una disminucion en el nivel de proteccion. Esto podria dar lugar a una mayor tasa de declaraciones de VIH en 2001, comparada con la observada en el ano 2000.
TCT-615 Impact of Mitral Annular Calcification on Clinical Outcomes after Transcatheter Aortic Valve Implantation
Authors: Marco Ancona, Francesco Giannini, Antonio Mangieri, Damiano Regazzoli, Luciano Candilio, Richard Jabbour, Akihito Tanaka, Francesco Ancona, Eustachio Agricola, Vittorio Romano, Manuela Giglio, Alaide Chieffo, Ottavio Alfieri, Matteo Montorfano, Antonio Colombo, Azeem Latib
Journal: Journal of the American College of Cardiology (2017)
Patients report worse care at GP clinics owned by limited companies
Authors: Gareth Iacobucci
Journal: BMJ (2017)

Patients registered at general practices in England that are owned by limited companies, including large organisations, reported worse experiences of care than other patients, a study has shown.

The research, published by the Journal of the Royal Society of Medicine ,1 examined data on 7949 general practices in England that were included in the General Practice Patient Survey 2013-14.

Researchers from Imperial College London examined …
Abstract 19308: Metoprolol Protects Against AMI Through the Inhibition of Psgl1-Dependent Neutrophil-platelet Interactions
Authors: Jaime Garcia-Prieto, Ines Garcia-Lunar, Monica Gomez-Parrizas, Rodrigo Fernandez-Jimenez, Gonzalo Pizarro, Vinatha Sreeramkumar, Rocio Villena-Gutierrez, Rafael Martinez-Bourio, Andres Hidalgo, Valentin Fuster, Borja Ibanez
Journal: Circulation (2015)

Introduction: Early intravenous administration of metoprolol has been shown to reduce infarct size and improve long-term cardiac function in the randomized clinical trial METOCARD-CNIC led by our group. However, the mechanisms underlying its favorable benefits remain unclear. PSGL1-dependent neutrophil-platelet interactions have critical implications on microvascular obstruction and neutrophil infiltration both of which determine the extent of infarct size. We hypothesized that intravenous administration of metoprolol before reperfusion blocks neutrophil-platelet interactions formation limiting the extent of infarct size. Methods &amp; Results: Using a mouse model of myocardial ischemia/reperfusion injury we confirmed that intravenous metoprolol administration prior to reperfusion significantly reduces infarct size. Neutrophil migration and infiltration evaluated in the injured myocardium after 6h of reperfusion was reduced in metoprolol’s treated mice. Neutrophil depletion, lack of beta-1-adrenergic receptor and PSGL1 blockade abrogated metoprolol’s cardioprotective effect. Interestingly, restitution of β1AR expression in circulating cells rescues the metoprolol′s cardioprotection. With a model of intravital microscopy we showed metoprolol systemic administration reduces neutrophil-platelet interactions after TNFα local inflammation. Additionally, metoprolol was capable to reduce epinephrine-induced neutrophil-platelet coaggregates formation in human blood. Finally, the extent of microvascular obstruction evaluated by cMRI in METOCARD-CNIC patients was significantly reduced by the pre-reperfusion administration of metoprolol. Conclusion: Intravenous administration of metoprolol exerts cardioprotection against AMI by inhibiting acute deleterious neutrophil-platelet interactions at reperfusion.
Using the power of the media to reduce the risk of suicide
Authors: Thomas Ungar, Stephanie Knaak, Cameron Norman
Journal: BMJ (2017)

Arendt and colleagues argue that international guidance on suicide and the media should be strengthened, implemented, and enforced.1

This approach can be enhanced by framing the matter as a human centred design challenge. Media and audiences are then considered to be cultural and contextual variables that can be designed for or around to produce a desired outcome. This may be particularly useful in a …
Abstract 20633: Use of Novel Compression Device Reduces the Incidence of Pocket Hematoma in Anticoagulated Patients Receiving Implantable Electronic Cardiac Devices: A Pilot Study
Authors: Dhanunjaya Lakkireddy, Krzysztof Bartus, Venkat Nagarajan, Rizwan Afzal, Donita Atkins, Vidhya Gunasekaran, Srijoy Mahapatra, Vijay Swarup
Journal: Circulation (2016)

Background: Pocket hematoma is a recognized complication after placement of cardiac implantable electronic devices (CIEDs) ranges from 2-5 %. It is associated with local discomfort, an increased ri...
Xpert MTB/RIF Ultra: the long-awaited game changer for tuberculous meningitis?
Authors: Jerome H. Chin
Journal: European Respiratory Journal (2017)

Mycobacterium tuberculosis (MTB) is the leading infectious cause of death globally and an estimated 10.4 million incident cases of tuberculosis (TB) and 1.8 million deaths occurred in 2015 [1]. Central nervous system TB, including tuberculous meningitis and brain tuberculomas, is challenging to diagnose and carries a high risk of severe disability and death [2]. Early diagnosis and prompt initiation of TB treatment offer the best chance of a good neurological outcome; however, an MTB culture of cerebrospinal fluid (CSF), the current reference standard for tuberculous meningitis, usually requires several weeks or longer for growth and is too slow for initial clinical decision-making. In addition, CSF microscopy using Ziehl–Neelsen staining has a very low sensitivity [2] and, as such, integration of clinical and laboratory findings, as well as neuroimaging results, is necessary in the majority of cases to make a probable or possible diagnosis of tuberculous meningitis in the absence of microbiological confirmation [2, 3]. Xpert MTB/RIF Ultra is a promising new technology to aid the diagnosis of tuberculous meningitis <http://ow.ly/pwCy30eORBm>
Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction
Authors: Elad Asher, Shir Tal, Israel Mazin, Arsalan Abu-Much, Avi Sabbag, Moshe Katz, Ehud Regev, Fernando Chernomordik, Victor Guetta, Amit Segev, Dan Elian, Israel Barbash, Paul Fefer, Michael Narodistky, Roy Beigel, Shlomi Matetzky
Journal: JAMA Cardiology (2017)

<h3>Importance</h3> Dual anti-platelet therapy represents standard care for treating patients with ST-segment elevation myocardial infarction (STEMI). Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation. <h3>Objective</h3> To evaluate whether chewing a loading dose (LD) of ticagrelor, 180 mg, vs traditional oral administration of an equal dose enhances platelet inhibition at 30 minutes and 1 hour after LD administration in patients with STEMI. <h3>Design, Setting, and Participants</h3> A randomized clinical trial was conducted in adults aged 30 to 87 years from May to October 2016 in a large tertiary care center. Analyses were intention-to-treat. <h3>Interventions</h3> Fifty patients with STEMI were randomized to either chewing an LD of ticagrelor, 180 mg, or standard oral administration of an equal dose. <h3>Main Outcomes and Measures</h3> P2Y12 reaction units were evaluated using VerifyNow (Accumentrics) at baseline, 30 minutes, 1 hour, and 4 hours after LD. <h3>Results</h3> Baseline characteristics were similar in both groups. The mean (SD) of P2Y12 reaction units in the chewing group compared with the standard group at baseline, 30 minutes, 1 hour, and 4 hours after ticagrelor LD were 224 (33) vs 219 (44) (95% CI, −16.77 to 27.73;<i>P</i> = .26), 168 (78) vs 230 (69) (95% CI, −103.77 to −19.75;<i>P</i> = .003), 106 (90) vs 181 (89) (95% CI, −125.15 to −26.29;<i>P</i> = .005), and 43 (41) vs 51 (61) (95% CI, −36.34 to 21.14;<i>P</i> = .30), respectively. Platelet reactivity in the chewing group was significantly reduced by 24% at 30 minutes after LD (95% CI, 19.75 to 103.77;<i>P</i> = .001). The relative inhibition of platelet aggregation in the chewing vs the standard group were 51% vs 10% (95% CI, 13.69 to 67.67;<i>P</i> = .005) at 1 hour and 81% vs 76% (95% CI, −12.32 to 16.79;<i>P</i> = .24) at 4 hours, respectively. Major adverse cardiac and cardiovascular event rate at 30 days was low (4%) and occurred in 1 patient in each group (95% CI, 0.06 to 16.93;<i>P</i> &gt; .99). <h3>Conclusions and Relevance</h3> Chewing an LD of ticagrelor, 180 mg, in patients with STEMI is feasible and facilitates better early platelet inhibition compared with a standard oral LD. Larger studies are warranted to see if our preliminary findings translate into clinical outcomes. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT02725099
Mandating Coverage for Fertility Preservation — A Step in the Right Direction
Authors: Eden R. Cardozo, Warren J. Huber, Ashley R. Stuckey, Ruben J. Alvero
Journal: New England Journal of Medicine (2017)

Connecticut and Rhode Island recently became the first U.S. states to mandate insurance coverage of fertility-preservation services for patients about to undergo a medical treatment — surgery, radiation, or chemotherapy — that may have deleterious effects on the gonads.
Metabolic activity by 18F-FDG-PET/CT to predict for early response after nivolumab in previously treated NSCLC.
Authors: Kyoichi Kaira, Ichiro Naruse, Tetsuya Higuchi, Bolag Alltan, Akira Mogi, Kimihiro Shimizu, Noriaki Sunaga, Takeshi Hisada, Takayuki Asao
Journal: Journal of Clinical Oncology (2017)

e20615 Background: Nivolumab, an immune checkpoint inhibitor and approved as an anti PD-1 drug, is administered to patients with previously treated non-small cell lung cancer (NSCLC). However, there are no established biomarkers to predict the efficacy of nivolumab. Here, we report a prospective study to investigate whether 2-[ 18 F]-fluoro-2-deoxy-D-glucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT) can predict therapeutic response after early-phase nivolumab treatment. Methods: Twenty-four patients who received nivolumab were enrolled from January to September 2016. 18 F-FDG-PET/CT was performed before and 1-month after nivolumab therapy. SUV max , SUV mean , metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were calculated in comparison with CT scan. We also analyzed the protein expression of PD-L1 and identified tumor infiltratrating lymphocytes (TILs) such as CD4-, CD8-, and Foxp3-positive cells within tumor specimens by immunohistochemistry. Correlation of response and nivolumab plasma concentration 1-month post therapy was analyzed. Results: Among the 24 patients, an early metabolic response to nivolumab was observed in 7 patients (29%) on SUV max , 6 patients (25%) on MTV, and 8 patients (33%) on TLG, whereas 7 (29%) patients achieved a partial response (PR) by RECIST. Out of the 7 patients with confirmed PR, early metabolic response by SUV max , SUV mean , MTV, and TLG were observed in 6 (85.7%), 5 (71.4%), 5 (71.4%) and 7 (100%) patients, respectively. However, only one patient (14.2%) yielded a PR by CT scan 1-month after nivolumab. All 9 (100%) patients with progressive metabolic disease by TLG had confirmed progressive disease (PD). Progression-free survival of more than 5 months was observed in all patients with early metabolic response by TLG. The morphological change by CT scan was not clearly identified as an early response. No significant correlation was found between metabolic response and nivolumab plasma concentration and expression of PD-L1 and TILs. Conclusions: Metabolic response calculation by TLG could be a better early-phase predictor of efficacy and survival after nivolumab in comparison with immune biomarkers such as PD-L1. Clinical trial information: UMIN000020814.
Recomendaciones europeas para el control y la prevención de la legionelosis asociada a viajes: la experiencia italiana
Authors: M C Rota, M R Caporali, M Massari
Journal: Eurosurveillance (2004)

En Italia, fueron identificadas 35 agrupaciones de legionelosis asociada a viajes entre julio de 2002, cuando se adoptaron las recomendaciones europeas sobre la vigilancia de la legionelosis por la red EWGLINET, y octubre de 2003. Ocho (28,6%) de ellas no hubieran sido detectadas sin la red. 
Las agrupaciones identificadas eran pequenas, de dos a seis casos y representaban un total de 87 pacientes. Cinco campings y 30 hoteles/residencias estaban implicados. El diagnostico, confirmado para el 92,0% de los casos, fue realizado principalmente por deteccion del antigeno en orina (84,7%). Un solo caso tenia un aislamiento clinico disponible. 
Siguiendo las investigaciones ambientales, se recogieron muestras desde los sistemas hidricos en 35 agrupaciones. Se identifico Legionella pneumophila en 23 casos (65,7%). En 15 lugares de alojamiento de los 35, las investigaciones estaban ya en curso en el momento de la notificacion de las agrupaciones a EWGLI. Esto se explica porque en Italia se realiza una investigacion ambiental completa tras la declaracion de cualquier caso aunque sea aislado. Se establecieron medidas de control en todos lugares a riesgo y fue cerrado un solo hotel. 
En las 35 agrupaciones, los informes fueron completados y enviados a tiempo, demostrando que es posible respetar los procesos exigidos por las recomendaciones europeas.
An Accessible Proteogenomics Informatics Resource for Cancer Researchers
Authors: Matthew C. Chambers, Pratik D. Jagtap, James E. Johnson, Thomas McGowan, Praveen Kumar, Getiria Onsongo, Candace R. Guerrero, Harald Barsnes, Marc Vaudel, Lennart Martens, Björn Grüning, Ira R. Cooke, Mohammad Heydarian, Karen L. Reddy, Timothy J. Griffin
Journal: Cancer Research (2017)

Proteogenomics has emerged as a valuable approach in cancer research, which integrates genomic and transcriptomic data with mass spectrometry-based proteomics data to directly identify expressed, variant protein sequences that may have functional roles in cancer. This approach is computationally intensive, requiring integration of disparate software tools into sophisticated workflows, challenging its adoption by nonexpert, bench scientists. To address this need, we have developed an extensible, Galaxy-based resource aimed at providing more researchers access to, and training in, proteogenomic informatics. Our resource brings together software from several leading research groups to address two foundational aspects of proteogenomics: (i) generation of customized, annotated protein sequence databases from RNA-Seq data; and (ii) accurate matching of tandem mass spectrometry data to putative variants, followed by filtering to confirm their novelty. Directions for accessing software tools and workflows, along with instructional documentation, can be found at z.umn.edu/canresgithub. Cancer Res; 77(21); e43-46. ©2017 AACR.
Botulismo en Noruega
Authors: M Kuusi, V Hasseltvedt, P Aavitsland
Journal: Eurosurveillance (1999)

El botulismo es una enfermedad paralizante grave causada por una toxina elaborada por Clostridium botulinum, bacilo anaerobio productor de esporas. Los medicos de Noruega estan obligados a declarar de inmediato al Instituto Nacional de Salud Publica (National Institute of Public Health -NIPH-) los casos de botulismo, por telefono y por correo en un impreso de declaracion especial. Han de resenarse el nombre del paciente, la edad, fecha de nacimiento, numero de identificacion y direccion, asi como la fuente sospechosa de la infeccion. Desde 1975, el NIPH dispone de una base de datos con todos los datos de vigilancia. El botulismo transmitido por alimentos es poco frecuente en Noruega y el botulismo, tanto del lactante como por heridas, se declararon por primera vez en 1997 (1). Un aumento reciente en el numero de casos de botulismo en Noruega (figura 1), ha resaltado la necesidad de realizar una labor de vigilancia, tanto para mejorar la identificacion de casos como para mantener unas medidas de prevencion.
Authors’ reply: Australian immunisation registers: established foundations and opportunities for improvement
Authors: L K Chin, N W Crawford, G Rowles, J P Buttery
Journal: Eurosurveillance (2012)

Preview this article: Authors’ reply: Australian immunisation registers: established foundations and opportunities for improvement, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/21/art20179-en-1.gif
Bichat recommandations sur la prise en charge clinique des patients présentant une brucellose lors d'un acte de bioterrorisme
Authors: P Bossi, A Tegnell, A Baka, F van Loock, A Werner, J Hendriks, H Maidhof, G Gouvras
Journal: Eurosurveillance (2004)

La Fievre Q est une zoonose due a Coxiella burnetii. Son interet comme arme biologique resulte du fait que l’aerosolization de quelques bacteries suffit a infecter les humains. La contamination alimentaire represente un autre mode de bioterrorisme. Cependant, C. burnetii ne semble pas etre un bon agent infectieux utilisable comme arme biologique car l’incubation de la maladie est longue, les presentations cliniques sont souvent frustres et la mortalite est faible. En cas d’attaque biologique utilisant C. burnetii, les formes cliniques seraient identiques a celles observees habituellement avec cette bacterie. Celles-ci peuvent etre asymptomatiques, aigues avec une pneumopathie ou une hepatite, ou chroniques sous forme d’endocardite par exemple. Cependant la plupart des presentations cliniques sont asymptomatiques et evoluent spontanement vers la guerison, et ce, en l’absence de traitement. Cependant, un traitement antibiotique peut diminuer la duree de l’evolution de l’infection et le risque d’evolution vers une endocardite. Une prophylaxie apres exposition a un aerosol est recommandee en cas d’attaque biologique.